|
Articles in Press
Value in Health offers readers the opportunity to access complete articles (Articles in Press) to be published in upcoming issues of Value in Health. Current Articles in Press can be found at: http://www.valueinhealthjournal.com, by clicking the “Articles in Press" tab.
Articles that appear in Articles in Press can be found in future issues of Value in Health listed below. All articles in these future issues have been accepted for publication, and currently may be at any stage in the post-acceptance process, which include copy-editing, typesetting, author review, revisions, and pre-electronic production, with articles in earlier issues appearing sooner than articles in later issues. These accepted articles appear in Articles in Press only after completing the post-acceptance process and remain for viewing until approximately one month prior the hard copy release date (Note: The timeframe from when an article is accepted, and appears and remains in Articles in Press are approximate, pending submission to publisher, extent of typesetting, author turn-around times, revisions, etc. Thus, some accepted articles that appear below may not appear in Articles in Press).
Future Issues:
Value in Health 2012 Volume 16
Issue 4
EDITORIALS
Editorial for ViH-03-2012-0103-MA.R1
ViH-02-2013-0085-ED Editorial to Computer Modeling of Diabetes and Its Complications: A Report on the Fifth Mount Hood Challenge Meeting John Hornberger
ViH-03-2013-0111-ED Reporting of Patient-Reported Outcomes in Randomized Trials: The CONSORT PRO Extension Donald Patrick
Editorial on Validation of Electronic Systems to Collect Patient-Reported Outcome (PRO) Data -- Recommendations for Clinical Trial Teams:
Report of the ISPOR ePRO Systems Validation Good Research Practices Task Force
Editorial for Developing Pediatric Patient-Reported Outcome Instruments for Clinical Trials to Support Medical Product Labeling: Report of the ISPOR Good Research Practices for the Assessment of PROs in Children and Adolescents Task Force
ISPOR TASK FORCE REPORTS
Validation of Electronic Systems to Collect Patient-Reported Outcome (PRO) Data -- Recommendations for Clinical Trial Teams:
Report of the ISPOR ePRO Systems Validation Good Research Practices Task Force
Developing Pediatric Patient-Reported Outcome Instruments for Clinical Trials to Support Medical Product Labeling: Report of the ISPOR Good Research Practices for the Assessment of PROs in Children and Adolescents Task Force
ECONOMIC EVALUATION
ViH-09-2011-0351-OM.R2 Value of information analysis from a societal perspective: a case study in prevention of major depression Leyla Mohseninejad, Pieter van Baal, Matthijs van den Berg, Erik Buskens, Talitha Feenstra
ViH-10-2012-0368-OM.R1 Cost-effectiveness of New Oral Anticoagulants Compared to Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation Doug Coyle, PhD, Kathryn Coyle, BScPharm, MSc, Chris Cameron, MSc, PhD (candidate), Karen Lee, MSc, Shannon Kelly, BA(hons), MSc (candidate), Sabine Steiner, MD, MSc, George A Wells, PhD
ViH-12-2011-0473-OM.R3 Cost-effectiveness of trabectedin plus pegylated liposomal doxorubicin hydrochloride for the treatment of women with relapsed platinum-sensitive ovarian cancer in the UK: Analysis based on the final survival data of the OVA-301 trial Fisher, Mark and Gore, Martin
ViH-06-2012-0208-OM.R2 Cost-effectiveness of early assisted discharge after COPD exacerbations in the Netherlands Lucas M.A. Goossens MSc, Cecile M.A. Utens MSc, Frank W.J.M. Smeenk MD PhD, Onno C.P. van Schayck PhD, Monique van Vliet MD, Walter van Litsenburg, Maria Braken, Maureen P.M.H. Rutten-van Mölken PhD
ViH-08-2012-0329-OM.R1 Probability elicitation to inform early health economic evaluations of new medical technologies: a case study in heart failure disease management Qi Cao, Msc; Douwe Postmus, PhD; Hans L. Hillege, PhD; Erik Buskens, PhD
Companion paper with ViH-11-2012-0420-OM.R1
ViH-11-2012-0419-OM.R1 EVALUATING THE COST-EFFECTIVENESS OF DIAGNOSTIC TESTS IN COMBINATION: IS IT IMPORTANT TO ALLOW FOR PERFORMANCE DEPENDENCY? Nicola Novielli, PhD, Nicola J Cooper, PhD, Alexander J Sutton, PhD
ViH-06-2012-0225-OM.R2 Using Whole Disease Modelling to inform resource allocation decisions: economic evaluation of a clinical guideline for colorectal cancer using a single model Paul Tappenden, BA, MSc, PhD, Jim Chilcott, BSc, MSc, Alan Brennan, BSc, MSc, PhD, Rob Glynne-Jones, FRCP, FRCR, Janine Youssef, MBChB, MRCS
PATIENT-REPORTED OUTCOMES
ViH-07-2012-0281-OM.R2 Examining Item Content and Structure in Health Status and Health Outcomes Instruments: Towards the Development of a Grammar for Better Understanding of the Concepts Being Measured Pennifer Erickson, PhD, Richard J. Willke, PhD
ViH-07-2012-0257-OM.R2 The mental component of the SF-12 as a measure of depressive disorders in the general population: results with three alternative scoring methods Gemma Vilagut MSc, Carlos G. Forero PhD, Alejandra Pinto PhD, Josep M. Haro MD, PhD, Ron de Graaf MD, PhD, Ronny Bruffaerts PhD, Viviane Kovess MD, PhD, Giovanni de Girolamo MD, Herbert Matschinger PhD,Montserrat Ferrer MD, PhD,Jordi Alonso MD,PhD on behalf of the ESEMeD investigators
ViH-02-2012-0044-OM.R2 Health related quality of life of ticagrelor versus clopidogrel in patients with acute coronary syndromes - Results from the PLATO-trial Lars-Åke Levin, PhD; Lars Wallentin, MD, PhD, Lars Bernfort, PhD, David Andersson, BA, Robert F. Storey, MD, DM, Gina Bergström, MSc, Carl-Johan Lamm, PhD, Magnus Janzon, MD, PhD, Padma Kaul, PhD
PREFERENCE-BASED ASSESSMENTS
ViH-03-2012-0111-OM.R3 Assessing the Value of Symptom Relief for Patients with Gastroesophageal Reflux Disease (GERD) Treatment: Willingness-to-Pay Using a Discrete Choice Experiment Ken Deal, MBA, PhD, FMRIA, CMRP, Deborah Marshall, PhD, Dominika Dabrowski, MSc, Alina Charter DVM, MSc, Margaret Bukoski, BSc, Paul Moayyedi BSc, MB ChB, PhD, MPH, FRCP (London), FRCPC, AGAF, FACG
ViH-10-2012-0374-OM.R3 Using a Survey to Estimate Health Expectancy and Quality Adjusted Life Expectancy to Assess Inequalities in Health and Quality of Life Brendan Collins
ViH-04-2012-0150-OM.R3 QALY and productivity loss: empirical evidence for “double counting” Takeru Shiroiwa, PhD, Takashi Fukuda, PhD, Shunya Ikeda, MD, PhD, Kojiro Shimozuma, MD, PhD
COMPARATIVE EFFECTIVENESS RESEARCH / HTA
ViH-04-2012-0158-OM.R2 Estimating the effectiveness of HPV-vaccination in the open population: a Bayesian approach. Willem Woertman, Ph.D., Gert Jan van der Wilt, Ph.D.
ViH-08-2012-0324-OM.R2 Radical Cystectomy versus Bladder Preserving Therapy for Muscle-Invasive Urothelial Carcinoma: Examining Confounding and Misclassification Bias in Cancer Observational Comparative Effectiveness Research Justin E. Bekelman, MD, Elizabeth A. Handorf, PhD, Thomas Guzzo, MD, MPH, Craig Evan Pollack, MD, John Christodouleas, MD, MPH, Matthew J. Resnick, MD, Samuel Swisher-McClure, MD, David Vaughn, MD, Thomas Ten Have, PhD, MPH, Daniel Polsky, PhD, and Nandita Mitra, PhD
Companion with ViH-11-2012-0419-OM.R1
ViH-11-2012-0420-OM.R1 META-ANALYSIS OF THE ACCURACY OF TWO DIAGNOSTIC TESTS USED IN COMBINATION: APPLICATION TO DDIMER AND WELLS SCORE FOR THE DIAGNOSIS OF DEEP VEIN THROMBOSIS Nicola Novielli PhD, Alexander J Sutton PhD, Nicola J Cooper PhD
HEALTH POLICY ANALYSIS
Companion with ViH-08-2012-0323-OM.R1
Measuring the Quality of a Childhood Cancer Care Delivery System: Quality Indicator Development Nicole M. E. Bradley MHSc, Paula D. Robinson MD MSc, Mark L. Greenberg ChB MB, Ronald D. Barr MB ChB MD FRCP (Glasg) FRCP (Lond) FRCPC FACP FRCPath FRCPHCH, Anne F. Klassen DPhil, Y. Lilian Chan PhD, Corin M. Greenberg PhD
Companion with ViH-08-2012-0321-OM.R1
ViH-08-2012-0323-OM.R1 Measuring the Quality of a Childhood Cancer Care Delivery System: Assessing Stakeholder Agreement Nicole M. E. Bradley MHSc, Paula D. Robinson MD MSc, Mark L. Greenberg ChB MB, Ronald D. Barr MB ChB MD FRCP (Glasg) FRCP (Lond) FRCPC FACP FRCPath FRCPHCH, Anne F. Klassen DPhil, Y. Lilian Chan PhD, Corin M. Greenberg PhD
ViH-07-2012-0286-OM.R1 Illustrating potential efficiency gains from using cost-effectiveness evidence to reallocate Medicare expenditures James D. Chambers PhD, MPharm, MSc, Joanne Lord MSc, PhD, Joshua T Cohen PhD, Peter J. Neumann ScD, Martin Buxton BA
METHODOLOGICAL ARTICLES
ViH-03-2012-0103-MA.R1 COMPUTER MODELING OF DIABETES AND ITS COMPLICATIONS: A REPORT ON THE FIFTH MOUNT HOOD CHALLENGE MEETING Prof. Andrew J. Palmer
ViH-07-2012-0274-PR.R2 A Checklist for Ascertaining Study Cohorts in Oncology Health Services Research Using Secondary Data: Report Of The ISPOR Oncology Good Outcomes Research Practices Working Group Kathy L. Schulman, MA, Karina Berenson, MPH, Ya-Chen (Tina) Shih, PhD, Kathleen A. Foley, PhD, Arijit Ganguli, MBA, PhD, Jonas de Souza MD, Alex Shteynshlyuger, MD
ViH-09-2011-0331-OM.R2 Systematic searching and selection of published health state utility values from the literature Diana Papaioannou (BChD, MSc), John Brazier (BA, MSc, PhD), Suzy Paisley (BA, MA)
Word Count: 4997
LETTERS TO THE EDITOR
ViH-01-2013-0024-LE Comparative Effectiveness in Personalized Medicine - Clearly Defining the Intended Use Population John Hornberger
ViH-02-2013-0063-LE Authors' response to "Comparative Effectiveness and Personalized Medicine" by Dr. J.C. Hornberger. Najafzadeh, Mehdi; Marra, Carlo; Lynd, Larry; Wiseman, Sam
Value in Health 2012 Volume 16
Issue 5
EDITORIAL
Editorial for ViH-11-2012-0406-COM.R1
ViH-03-2013-0096-ED How should we value future health? Was NICE right to change? James Raftery
ISPOR TASK FORCE REPORTS
ViH-04-2013-0148-TFR Performance-Based Risk-Sharing Arrangements— Good Practices for Design, Implementation, and Evaluation: An ISPOR Task Force Report Louis P. Garrison, Jr., PhD, Adrian Towse, MA, MPhil, Andrew Briggs, MSc, DPhil, Gerard de Pouvourville, PhD, Jens Grueger, PhD, Penny Mohr, MA, J.L. (Hans) Severens PhD, Paolo Siviero, BA, Miguel Sleeper, ACMA
ECONOMIC EVALUATION
ViH-02-2011-0082-OM.R4 Value of research and value of development in early assessments of new medical technologies Valesca P Retèl, PhD, Janneke PC Grutters, PhD, Wim H van Harten, MD, PhD, Manuela A Joore, PhD
ViH-10-2012-0376-OM.R1 Cost-effectiveness of the 21-gene assay for guiding adjuvant chemotherapy decisions in early breast cancer Mike Paulden, MSc; Jacob Franek, MHSc; Ba’ Pham, MSc; Philippe L. Bedard, MD; Maureen Trudeau, MD; Murray Krahn, MD
ViH-05-2012-0194-BR.R2 Compensation mechanisms for lost productivity: A comparison between four European countries S Knies, A Boonen, MJJM Candel, SMAA Evers, JL Severens
ViH-06-2012-0222-OM.R2 Economic Analysis of the Intangible Impacts of Informal Care for People with Alzheimer’s Disease and Other Mental Disorders Co-authors: C. G, M M. B, J. A
ViH-05-2012-0189-BR.R2 Potential cost-effectiveness of pneumococcal conjugate vaccine (PCV) in Turkey Özden Türel MD, Adnan Kisa M.S.P.H., PhD, E. David G McIntosh MBBS MPH LLM PhD, Mustafa Bakir MD
ViH-09-2012-0336-OM.R3 Transarterial Chemoembolization Treatment: Association between Multiple Treatments, Cumulative Expenditures, and Survival Ian M. Breunig, PhD, Fadia T. Shaya, PhD, MPH, Nader Hanna, MD, FACS, FICS, Brian Seal, RPh, MBA, PhD, Viktor V. Chirikov, MS, C. Daniel Mullins, PhD
ViH-07-2012-0245-OM.R2 Gastroprotective strategies in chronic NSAID users: a cost-effectiveness analysis comparing single tablet formulations with individual components N.L. de Groot, B.M.R. Spiegel, H.G.M van Haalen, N.J. de Wit, P.D. Siersema, M.G.H. van Oijen
PATIENT-REPORTED OUTCOMES
ViH-10-2012-0384-OM.R1 HEALTH UTILITY ASSESSMENT USING EQ-5D AMONG CAREGIVERS OF CHILDREN WITH AUTISM Rahul Khanna, MBA, Ph.D., Krutika Jariwala, MS, John P. Bentley, MBA, Ph.D.
ViH-09-2012-0353-OM.R2 Development and Initial Validation of the NCCN/FACT Symptom Index for Advanced Kidney Cancer Nan E. Rothrock, Ph.D, Sally E. Jensen, Ph.D, Jennifer L. Beaumont, M.S, Amy P. Abernethy, M.D, Paul B. Jacobsen, Ph.D, Karen Syrjala, Ph.D, David Cella, Ph.D
PREFERENCE-BASED ASSESSMENTS
ViH-09-2012-0346-SR.R1 Willingness to Pay for Diagnostic Technologies: A Review of the Contingent Valuation Literature Pei-Jung Lin, Ph.D., Michael J. Cangelosi, M.A., M.P.H., David W. Lee, Ph.D., Peter J. Neumann, Sc.D.
ViH-04-2012-0151-OM.R2 Does the process of deliberation change individual’s health state valuations?: an exploratory study using the Person Trade Off Technique Suzanne Robinson and Stirling Bryan
ViH-11-2012-0424-OM.R1 Italian population-based values of EQ-5D health states L Scalone ScD PhD, PA Cortesi MSc, R Ciampichini MSc, A Belisari MSc, LS D’Angiolella PhramD, Cesana G MD, LG Mantovani DSc
ViH-07-2012-0262-OM.R2 Health Utilities after Adjustable Gastric Banding:An Application of Nonlinear Models Vincent W. Lin, Pharm.D., M.S, Edwin S. Wong., Ph.D, Andrew Wright, M.D, David R. Flum, M.D., M.P.H, Louis P. Garrison, Jr., Ph.D, Rafael Alfonso-Cristancho, M.D., M.Sc., Ph.D, Sean D. Sullivan, Ph.D
COMPARATIVE EFFECTIVENESS RESEARCH / HTA
ViH-07-2012-0254-OM.R1 Reviewing the evidence to inform the population of cost-effectiveness models within health technology assessments. Dr Eva Kaltenthaler, BSc, MSc, PhD, Dr Paul Tappenden, BA, MSc, PhD, Dr Suzy Paisley, BA, MA, PhD
ViH-06-2012-0212-OM.R1 Updating the Canadian Hemophilia Outcomes - Kids Life Assessment Tool (CHO-KLAT Version 2.0) Nancy L. Young, Cindy Wakefield, Tricia A. Burke, Randi Ray, Patricia J McCusker, Victor Blanchette
HEALTH POLICY ANALYSIS
ViH-01-2013-0029-OM.R1 Which is More Valuable, Longer Survival or Better Quality of Life? Israeli Oncologists' and Family Physicians' Attitudes toward the Relative Value of New Cancer and Congestive Heart Failure Interventions Dan Greenberg, Ph.D., Ariel Hammerman, Ph.D, Shlomo Vinker, M.D, Adi Shani, M.D, Yuval Yermiahu, MHA, Peter J. Neumann, Sc.D
METHODOLOGICAL ARTICLES
ViH-07-2012-0263-MA.R2 Validating and improving the reliability of the EORTC QLQ-C30 using a multidimensional Rasch model Ching-Lin Shih, PhD; Chien-Hung Chen, MD, PhD; Ching-Fan Sheu, PhD; Hui-Chu Lang, PhD; Ching-Lin Hsieh (equal contribution as the corresponding author), PhD
SYSTEMATIC REVIEWS
ViH-10-2012-0397-BR.R1 How should we deal with patient heterogeneity in economic evaluation: a systematic review of national pharmacoeconomic guidelines Bram L.T. Ramaekers, MSc, Manuela A. Joore, PhD, Janneke P.C. Grutters, PhD
ViH-12-2011-0470-OM.R3 Impact of interventions on medication adherence and blood pressure control in patients with essential hypertension: a systematic review by the ISPOR Medication Adherence & Persistence Special Interest Group Femida H. Gwadry-Sridhar, BSc, Pharm, MSc(Epi), PhD, Elizabeth Manias, RN, CertCritCare, BPharm, MPharm, MNStud, PhD, FRCNA, Lincy Lal, PharmD, PhD, Maribel Salas, MSc, DSc, MD, Dyfrig A. Hughes, BPharm, MSc, PhD, MRPharmS, Alexandria Ratzki-Leewing, BHSc, MSc (Candidate), Maja Grubisic, BSc, MSc
ViH-09-2012-0364-SR.R2 Efficacy, Patient-reported Outcomes (PROs), and Tolerability of the Changing Therapeutic Landscape in Patients with Metastatic Prostate Cancer (MPC): A Systematic Literature Review Brian S. Seal, PhD, RPh, MBA; Carl V. Asche, PhD, MBA; Katarzyna Puto, PharmD, MBA, BCOP, BCPS; Pamela D. Allen, PharmD, MBA
ViH-05-2012-0180-SR.R3 A Systematic Literature Review of Psychosocial and Behavioral Factors Associated with Initial Medication Adherence: A Report of the ISPOR Medication Adherence & Persistence Special Interest Group John E. Zeber, PhD, Elizabeth M. Manias, PhD, Allison F. Williams, PhD, David Hutchins, MHSA, MBA, Waka A. Udezi, PhD, Craig S. Roberts, PharmD, MBA, Andrew M. Peterson, PharmD, PhD
POLICY PERSPECTIVES
ViH-08-2012-0325-PS.R1 Deciding which drugs get onto the formulary: A Value Approach Raymond J. Seigfried, MA, Teresa Corbo, Pharm.D, Mitchell T. Saltzberg, MD, FACC, FAHA, Jeffrey Reitz, PharmD, MPH
COMMENTARIES
**Editorial from James Raftery
ViH-11-2012-0406-COM.R1 NICE’s Selective Application of Differential Discounting: Ambiguous, Inconsistent and Unjustified James F O’Mahony, MA & Mike Paulden, MSc, MA
Value in Health Main
Page
|
